1.

Record Nr.

UNINA9910457003903321

Autore

Leibniz Gottfried Wilhelm, Freiherr von, <1646-1716.>

Titolo

Dissertation on predestination and grace [[electronic resource] /] / G.W. Leibniz ; translated, edited, and with an introduction by Michael J. Murray ; additional contributions by George Wright

Pubbl/distr/stampa

New Haven, : Yale University Press, c2011

ISBN

1-283-09608-0

9786613096081

0-300-15571-9

Descrizione fisica

1 online resource (226 p.)

Collana

The Yale Leibniz

Altri autori (Persone)

MurrayMichael J

WrightGeorge

Disciplina

234/.9

Soggetti

Grace (Theology)

Predestination

Electronic books.

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and indexes.

Nota di contenuto

Frontmatter -- Contents -- Preface -- Abbreviations -- A Note on the Texts and Translations -- Introduction -- Article XVII of and Burnet's Commentary on The Thirty-Nine Articles of the Church of England -- Leibniz's Commentary on Burnet -- Notes -- Suggestions for Further Reading -- Index of Names -- Index of Subjects

Sommario/riassunto

In this book G. W. Leibniz presents not only his reflections on predestination and election but also a more detailed account of the problem of evil than is found in any of his other works apart from the Theodicy. Surprisingly, his Dissertation on Predestination and Grace has never before been published in any form. Michael J. Murray's project of translating, editing, and providing commentary for the volume will therefore attract great interest among scholars and students of Leibniz's philosophy and theology. Leibniz addresses such topics as free will, moral responsibility, divine causation, justice, punishment, divine foreknowledge, and human freedom, revealing crucial aspects of the genesis of his mature metaphysics and the theological motivations behind it.



2.

Record Nr.

UNINA9910437619503321

Autore

Maximov Philipp Y

Titolo

Tamoxifen : pioneering medicine in breast cancer / / Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan

Pubbl/distr/stampa

Basel, : Springer, 2013

ISBN

3-0348-0664-7

Edizione

[1st ed. 2013.]

Descrizione fisica

1 online resource (218 p.)

Collana

Milestones in drug therapy

Altri autori (Persone)

JordanV. Craig (Virgil Craig)

McDanielRussell E

Disciplina

616.99449061

Soggetti

Tamoxifen

Breast - Cancer - Chemoprevention

Breast - Cancer - Chemotherapy

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references.

Nota di contenuto

Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens -- Tamoxifen Goes Forward Alone -- Metabolites of Tamoxifen as the Basis of Drug Development -- Adjuvant Therapy – The Breakthrough -- The Wisconsin Story in the 1980’s: Discovery of Target Site Specific Estrogen Action -- Carcinogenesis and Tamoxifen -- Chemoprevention: Cinderella waiting for the ball -- Tamoxifen and Raloxifene head to head: The STAR TRIAL -- Acquired resistance to Tamoxifen: back to the beginning -- The legacy of Tamoxifen -- Appendix: Four decades of discovery in breast cancer research and treatment – an interview with V. Craig Jordan by Marc Poirot -- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine.

Sommario/riassunto

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his



four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.